Dual antithrombotic therapy by hospital discharge is recommended for most patients with atrial fibrillation undergoing PCI, reserving triple therapy for those at high ischemic and low bleeding risk.
What is the optimal antithrombotic management for patients with atrial fibrillation on oral anticoagulation undergoing percutaneous coronary intervention?
This expert consensus document updates recommendations to favor early aspirin discontinuation in most AF patients undergoing PCI to balance ischemic and bleeding risks.
inhibitor) by the time of hospital discharge should be considered for most patients, whereas extending the use of aspirin beyond hospital discharge (ie, triple therapy) should be considered only for selected patients at high ischemic/thrombotic and low bleeding risks and for a limited period of time. The present document provides a focused updated on the rationale for the new expert consensus-derived recommendations on the antithrombotic management of patients with atrial fibrillation treated with oral anticoagulation undergoing percutaneous coronary intervention.
Angiolillo et al. (Tue,) conducted a review in Atrial fibrillation treated with oral anticoagulation undergoing percutaneous coronary intervention. Antithrombotic therapy was evaluated. Dual antithrombotic therapy by hospital discharge is recommended for most patients with atrial fibrillation undergoing PCI, reserving triple therapy for those at high ischemic and low bleeding risk.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: